Castle Biosciences (NASDAQ:CSTL) Given New $44.00 Price Target at Robert W. Baird

Castle Biosciences (NASDAQ:CSTL) had its price target increased by Robert W. Baird from $41.00 to $44.00 in a report published on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other research analysts have also issued reports on CSTL. KeyCorp reissued an “overweight” rating and issued a $50.00 target price on shares of Castle Biosciences in a research report on Thursday, January 29th. BTIG Research increased their price objective on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Lake Street Capital boosted their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a report on Monday, January 12th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, February 2nd. Finally, Guggenheim lifted their price target on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.57.

Castle Biosciences Trading Down 7.2%

NASDAQ CSTL traded down $2.31 during trading on Friday, hitting $29.57. The company had a trading volume of 926,930 shares, compared to its average volume of 431,636. The company’s fifty day moving average is $37.17 and its 200-day moving average is $31.13. Castle Biosciences has a one year low of $14.59 and a one year high of $44.28. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02. The company has a market cap of $863.15 million, a price-to-earnings ratio of -34.79 and a beta of 1.06.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. The company had revenue of $81.88 million for the quarter, compared to analysts’ expectations of $81.19 million. On average, sell-side analysts predict that Castle Biosciences will post 0.44 earnings per share for the current year.

Insider Activity

In other Castle Biosciences news, insider Derek J. Maetzold sold 817 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total transaction of $31,037.83. Following the completion of the sale, the insider directly owned 83,698 shares in the company, valued at approximately $3,179,687.02. This trade represents a 0.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kristen M. Oelschlager sold 14,888 shares of Castle Biosciences stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total transaction of $585,247.28. Following the completion of the transaction, the chief operating officer directly owned 12,323 shares of the company’s stock, valued at $484,417.13. This trade represents a 54.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 29,617 shares of company stock worth $1,167,887 over the last three months. 6.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CSTL. RTW Investments LP bought a new stake in Castle Biosciences in the 4th quarter worth approximately $82,283,000. AIGH Capital Management LLC bought a new stake in shares of Castle Biosciences in the third quarter worth $16,105,000. Summit Partners Public Asset Management LLC increased its position in Castle Biosciences by 164.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares during the last quarter. Braidwell LP lifted its holdings in Castle Biosciences by 125.3% in the second quarter. Braidwell LP now owns 822,735 shares of the company’s stock valued at $16,800,000 after acquiring an additional 457,488 shares during the period. Finally, Eventide Asset Management LLC purchased a new position in Castle Biosciences in the fourth quarter worth about $11,864,000. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences News Summary

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results and 2026 revenue guide: Castle reported FY2025 revenue of $344M (above guidance) with Q4 revenues roughly in line with estimates and beat on EPS (Q4 GAAP EPS -$0.08 vs. consensus -$0.23). Management set 2026 revenue guidance of $340–$350M (slightly above the prior consensus ~$335M), supporting near‑term top‑line growth expectations. Castle Biosciences outlines 2026 revenue target
• Positive Sentiment: Product momentum and new launch: Core test reports (DecisionDx‑Melanoma and TissueCypher) rose ~37% in 2025 (TissueCypher +86%), and Castle launched AdvanceAD‑Tx (limited access), which expands the addressable market in atopic dermatitis. These operational wins support longer‑term growth potential. Earnings press release
• Positive Sentiment: Analyst upgrade / price target lift: Robert W. Baird raised its price target to $44 and reiterated an Outperform rating, signaling bullish analyst sentiment and implying notable upside from current levels. Baird raises target
• Neutral Sentiment: Additional coverage & materials: Earnings and investor materials (call transcript, slide deck) are available for deeper due diligence — useful for active investors reviewing guidance detail and management commentary. Press release & slide deck
• Neutral Sentiment: Street view: Recent coverage shows a generally constructive analyst stance (average “Moderate Buy” / multiple buy/outperform ratings), which can support sentiment if fundamentals hold. Analyst ratings roundup
• Negative Sentiment: Profitability and accounting headwinds: Despite revenue growth, Castle reported a GAAP net loss for 2025 of $24.2M (vs. net income in 2024) and adjusted EBITDA declined materially (from $75M to $44M). A one‑time acceleration of amortization (IDgenetix) and other items reduced margins — a drag on near‑term earnings power. Zacks earnings summary
• Negative Sentiment: Insider selling and discontinued tests: Public filings and summaries show heavy insider sales in recent months and the discontinuation of IDgenetix (lost volume), both of which can pressure sentiment and raise governance/operational questions for investors. Quiver / results summary

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.